A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

The acting deputy attorney general accused FBI leadership of “insubordination” by refusing to identify a “core team” of ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Cencora simplifies distribution logistics by shipping products to centralized wholesaler locations, as opposed to shipping directly to pharmacies and various customer locations. Additionally, Cencora ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

Management provided Q4 revenue guidance in the range of $650 million to $710 million, reflecting backlog strength and anticipated sequential growth. Hider noted that transportation revenues are ...

Q1 2025. Management View. CEO Robert Mauch highlighted strong Q1 performance with 13% revenue growth and a 14% increase in adjusted EPS.

Recently, there has been a lot of buzz around GLP-1 weight loss injections. Talk of Ozempic or Wegovy has been hard to miss.

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

Led by an interest in GLP-1 weight loss drugs, more health care brands may advertise in the Super Bowl this year.

The pooled prevalence of chronic painful neuropathy is 41.22 percent among individuals with chemotherapy-induced peripheral ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.